Moleculin Biotech Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Moleculin Biotech stock.
View analyst ratings for Moleculin Biotech or view top-rated stocks.

Wall Street analysts have given Moleculin Biotech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Moleculin Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Moleculin Biotech saw a decrease in short interest during the month of May. As of May 28th, there was short interest totaling 944,700 shares, a decrease of 14.9% from the May 13th total of 1,110,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 0.8 days. Currently, 3.5% of the shares of the stock are sold short.
View Moleculin Biotech's Short Interest.

Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Moleculin Biotech.

Moleculin Biotech, Inc. (NASDAQ:MBRX) announced its earnings results on Tuesday, May, 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.03.
View Moleculin Biotech's earnings history.

Moleculin Biotech's stock was trading at $3.0306 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MBRX stock has increased by 27.4% and is now trading at $3.86.
View which stocks have been most impacted by COVID-19.

Moleculin Biotech shares reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of Moleculin Biotech stock prior to the reverse split would have 17 shares after the split.

1 analysts have issued 1-year price objectives for Moleculin Biotech's shares. Their forecasts range from $12.00 to $12.00. On average, they expect Moleculin Biotech's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 210.9% from the stock's current price.
View analysts' price targets for Moleculin Biotech or view top-rated stocks among Wall Street analysts.

Some companies that are related to Moleculin Biotech include Viking Therapeutics (VKTX), Oramed Pharmaceuticals (ORMP), Oncorus (ONCR), Viracta Therapeutics (VIRX), ANI Pharmaceuticals (ANIP), Tonix Pharmaceuticals (TNXP), Inozyme Pharma (INZY), Verona Pharma (VRNA), Cue Biopharma (CUE), Amryt Pharma (AMYT), Fortress Biotech (FBIO), Homology Medicines (FIXX), Kala Pharmaceuticals (KALA), VistaGen Therapeutics (VTGN) and DURECT (DRRX).
View all of MBRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

Moleculin Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.84%), Geode Capital Management LLC (0.61%), Northern Trust Corp (0.18%), Squarepoint Ops LLC (0.10%), Cubist Systematic Strategies LLC (0.09%) and Occudo Quantitative Strategies LP (0.08%).
View institutional ownership trends for Moleculin Biotech.

MBRX stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Taylor Cottrill Erickson & Associates Inc., and Northern Trust Corp.
View insider buying and selling activity for Moleculin Biotech or view top insider-selling stocks.

MBRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Cubist Systematic Strategies LLC, Occudo Quantitative Strategies LP, Squarepoint Ops LLC, Citadel Advisors LLC, Citadel Advisors LLC, Harel Insurance Investments & Financial Services Ltd., and Morgan Stanley.
View insider buying and selling activity for Moleculin Biotech or or view top insider-buying stocks.

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MBRX stock can currently be purchased for approximately $3.86.

Moleculin Biotech has a market capitalization of $109.78 million. The company earns $-17,350,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

Moleculin Biotech employs 10 workers across the globe.

The official website for Moleculin Biotech is www.moleculin.com.

Moleculin Biotech is headquartered at 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007.

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160 or via email at [email protected]